Nobritol

Quick links to important sections

Nobritol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nobritol

Here are the key characteristics of Nobritol, focusing strictly on its identity and composition.

Property Description
Active ingredient Amitriptyline and Medazepam
Form Fixed-dose oral capsule
Pharmacological class Combination Psychotropic
General purpose Mood elevation and tension relief
Origin Synthetic

What Type of Medicine is Nobritol?

Nobritol is a synthetic, prescription-only (Rx) fixed-dose combination psychotropic drug, integrating two agents from distinct therapeutic classes. This pharmacological classification means the medication combines both an antidepressant and an anxiolytic (anti-anxiety) agent into a single system, delivered as an oral capsule for adults. The fixed-dose nature is clinically recognized for promoting consistent delivery of both components simultaneously, which is often crucial for managing complex symptom patterns.


What is Nobritol’s Active Composition?

The core active ingredients are Amitriptyline and Medazepam, defining the medication's dual mechanism of action. Amitriptyline is classified as a Tricyclic Antidepressant (TCA), a class of drugs known for regulating mood by affecting neurochemical messengers in the brain. The Medazepam component is a Benzodiazepine, which is recognized for its ability to reduce excessive nervous system activity, providing a calming influence. This specific combination is often considered in therapeutic contexts where a patient presents with symptoms of depression accompanied by prominent anxiety, tension, or restlessness, a typical use scenario for this pairing.


What is the General Purpose of This Combination?

The general purpose of this combination is to achieve comprehensive emotional equilibrium by simultaneously providing both mood elevation and tension relief. The drug is specifically formulated to merge the core antidepressant action of the TCA component with the anxiolytic effect of the benzodiazepine component. Integrating components with different mechanisms of action is an established strategy for managing co-occurring mood and anxiety symptoms. This approach aims to provide a more complete initial management approach than using either component alone.

Regulatory References

  1. Amitriptyline FDA Label (NIH DailyMed)
  2. Amitriptyline (NIH StatPearls)

What side effects are possible with Nobritol?

Possible Side Effects and Safety Information

The official safety profile for Nobritol is structured to highlight both common, expected adverse reactions and rare, serious safety concerns as documented by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the frequency reported in clinical trials and post-marketing surveillance:

  • Very Common (may affect ge 1 in 10 users): Includes reactions such as dry mouth, drowsiness, and dizziness.
  • Common (may affect up to 1 in 10 users): May include effects such as constipation, weight gain, and tremor.
  • Uncommon, Rare, or Very Rare: These categories cover less frequent side effects involving various body systems.

Serious and Clinically Significant Safety Concerns

The regulatory documentation identifies specific risks that require careful consideration:

  • Cardiac Safety: Serious effects on the heart are documented, including the risk of QT interval prolongation (an electrical disturbance of the heart) and life-threatening rhythm disturbances such as Torsades de pointes. This medicine is contraindicated in patients with a history of congenital long QT syndrome.
  • Suicidal Risk: Regulatory agencies require a boxed warning concerning the increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to 25 years old), particularly when initiating treatment or changing the dose.
  • Severe Systemic Reactions: Rare but severe adverse events are documented, including Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS), and severe allergic reactions affecting the skin and internal organs, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
  • Risk of Withdrawal Phenomena: Abruptly stopping or significantly reducing the dose may result in withdrawal symptoms, which are documented to include anxiety, restlessness, and sleep disturbances.

Safety Limitations

The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Caution is noted for use in elderly patients due to their increased sensitivity to adverse effects, especially cardiac effects. Use in patients with a history of seizures also requires particular caution.

Overdose and Emergency Response

Overdose and when to Seek Help

Nobritol is a fixed-dose combination containing an agent with known cardiotoxicity, and any suspected overdose requires immediate, urgent medical intervention due to the potential for severe and life-threatening effects.


Documented Manifestations and Severe Outcomes

Overdose symptoms may include severe Central Nervous System ( CNS) effects such as disorientation, stupor, agitation, hallucinations, and progression to seizures and coma. Cardiovascular complications are officially documented and include hypotension, ECG changes like QRS prolongation, and potentially fatal ventricular arrhythmias. Anticholinergic signs, such as mydriasis (dilated pupils) and urinary retention, are also noted. Children are documented as being especially susceptible to severe cardiotoxicity and neurological complications following an overdose.


Emergency Action and Management

Due to the high risk of severe cardiotoxicity and CNS depression, individuals must seek immediate medical help right away for any suspected overdose. Treatment is officially defined as symptomatic and supportive, requiring hospital admission and continuous cardiac monitoring ( ECG) for a minimum of 12 hours for symptomatic patients.

No specific antidote is known for the main toxic component, and the administration of Flumazenil (an antidote for pure benzodiazepine toxicity) is explicitly advised against in this combined overdose scenario. Supportive measures, such as activated charcoal, may be used depending on the severity and timing of the ingestion.

Therapeutic Uses of Nobritol

What Nobritol Treats: Main Uses and Benefits

Nobritol is relevant for symptomatic relief in the management of depressive states that are complicated by tension, nervousness, or psychomotor agitation. This approach is commonly used to help with conditions characterized by periods of heightened symptoms, specifically depression associated with prominent anxiety.

The medication is relevant for easing the complex cluster of symptoms, including low mood and restlessness, and may assist with maintaining a sense of stability by addressing tension. It is used for managing conditions that present with dual symptomatic burden, which may include chronic tension headache, periodic migraine prophylaxis, or certain neuropathic pain syndromes. The medication contributes to easing the overall symptom load during difficult episodes.

“The treatment may support patients during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods.”


Quick Fact: Symptomatic Support for Somatic Distress

This medication may assist with addressing symptoms related to physical discomfort, often associated with psychological tension, and may assist with managing associated sleep disturbances that create noticeable functional strain.

Eligibility and Restrictions for Use

Nobritol, a combination medication containing amitriptyline (a tricyclic antidepressant) and medazepam (a benzodiazepine), is typically prescribed for patients experiencing anxiety and depressive states that require both antidepressant and sedative effects.


Who May Use Nobritol?

It is indicated for adults with specific neurotic, anxious, or reactive depressive syndromes. Treatment should generally be limited in duration, typically not exceeding 8–12 weeks, to minimize the risk of dependence, particularly due to the medazepam component. It may also be considered for children over the age of six for nocturnal enuresis, but usually after other options have failed.


Who Should NOT Use Nobritol?

Use of Nobritol is generally contraindicated in patients with a history of recent heart attack (myocardial infarction) or certain heart rhythm problems (e.g., QT prolongation). It should also be avoided by individuals with:

  • Glaucoma (specifically, angle-closure glaucoma).
  • Severe liver disease or respiratory insufficiency (e.g., severe sleep apnea syndrome).
  • Known hypersensitivity to amitriptyline, medazepam, or any of the medication's components.
  • Simultaneous use of Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping an MAOI.

It is also advised to avoid its use in patients with drug or alcohol dependency, unless under strict medical supervision.

What should I know about interactions with other medicines?

Nobritol Interactions with other medicines and products

The interaction profile for Nobritol is defined by the combined pharmacological actions of its two components, Amitriptyline and Medazepam, requiring strict adherence to regulatory restrictions. All following information is based on official government documentation.


Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the high risk of severe reactions, including the development of serotonin syndrome. A mandatory minimum of 14 days must elapse between discontinuing an MAOI and beginning Nobritol treatment. Combination with other QTc-prolonging agents (e.g., Cisapride, certain Type 1A/1C Antiarrhythmics) is also contraindicated because of the additive effect on the QTc interval and increased risk of arrhythmias.


Documented Pharmacodynamic and Metabolic Interactions

The most clinically significant pharmacodynamic interactions involve Central Nervous System (CNS) Depressants, including Opioid Analgesics. Co-use with these agents is associated with serious risk, specifically profound sedation and respiratory depression, due to additive effects. Furthermore, substances that inhibit the metabolic enzyme CYP2D6 or the P-glycoprotein transporter can cause a pharmacokinetic interaction. This effect results in a significant increase in the plasma concentration of the Amitriptyline component and potential toxicity.


Non-Medicinal Substances and Population Notes

Consumption of Alcohol (Ethanol) is strictly avoided as it enhances the CNS depressant effects of the medicine. Regulatory documentation also advises that precautions are necessary when treating patients with impaired hepatic function due to the potential for slower clearance and subsequent increased exposure to the medication.

Mechanism of Action

Dual Regulation of Inhibitory and Monoamine Systems

Nobritol's mechanism relies on the concurrent action of two distinct components. One rapidly enhances the function of the GABA-A receptor complex—the brain's major inhibitory pathway—by positive allosteric modulation, resulting in neuronal hyperpolarization and reduced overall CNS excitability. The other component initiates a sustained effect by inhibiting the reuptake of Serotonin ( SERT) and Norepinephrine ( NET) transporters, gradually increasing these monoamine levels to support the long-term modulation of affective pathways.


⏳ Complementary Mechanistic Onset Kinetics

The resulting CNS activity profile is defined by the temporal difference in the two mechanisms. The GABA enhancement mechanism operates with a rapid onset, producing rapid enhancement of central inhibitory tone, affecting CNS excitability within minutes to hours. In contrast, the sustained monoamine regulation mechanism requires several weeks for the necessary molecular and cellular changes (neuroplasticity) to fully manifest, linking rapid inhibitory pathway modulation with the slower changes in monoamine signaling.


Constraints of Non-Selective Receptor Binding

A constraint on the mechanism is the non-selective affinity of the monoamine-regulating component for several off-target receptors, including Histamine H1, Muscarinic Cholinergic M1, and Alpha-1 Adrenergic alpha1. The antagonism at these non-primary sites imposes limits on the molecule's selectivity and influences systemic physiological functions outside of its intended central SERT/ NET reuptake inhibition.

Dosage and Administration Information

Nobritol is administered exclusively via the oral route as a fixed-dose tablet or capsule. This form of administration ensures both active components, an antidepressant and an anxiolytic, are delivered simultaneously.


Standard Dosage Regimens

Dosing typically begins at a low initial level for adults, such as a 5 mg/12.5 mg or 10 mg/25 mg strength (benzodiazepine/amitriptyline) taken three or four times daily in divided doses. The total daily dose may be adjusted up to a specified maximum, such as six dosage units per day, depending on the patient's clinical needs. Once a satisfactory response is achieved, the practice involves a dose reduction to the lowest amount necessary for maintenance.


Timing and Special Instructions

Administration is often scheduled to include the largest portion of the daily dose, or a single dose, taken at bedtime. This specific timing is utilized to help manage the sedative properties inherent to the drug combination. The medicine can generally be taken with or without food. Due to the inclusion of a benzodiazepine, treatment is generally intended for a limited duration of use. Upon cessation, the established protocol requires a gradual dose reduction (tapering) over time; sudden discontinuation is not advised.


Population Adjustments

Lower dosages are generally recommended for older adults. This adjustment accounts for the higher sensitivity to the active ingredients and altered metabolism in geriatric patients. Usual precautions must also be observed for patients with impaired renal or hepatic function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nobritol

Research examining this combination therapy includes studies of the combination itself and the broader evidence base for its individual components, Amitriptyline and Medazepam, when used in similar therapeutic strategies. The evidence highlights what has been explored by researchers and what patterns have been observed so far, without offering individual predictions or clinical guidance.


Evidence for Depressive States Complicated by Anxiety and Tension

The research has primarily examined the combination in adult patients experiencing co-occurring symptoms, specifically conditions characterized by low mood, prominent anxiety, tension, or restlessness.

Researchers utilized Randomized Controlled Trials (RCTs) and various systematic reviews to explore how symptoms change over defined time intervals. These studies examined outcomes related to antidepressant status, standardized scales for measuring anxiety and tension severity, general outcomes reflecting daily functioning or activity level, and also monitored safety as a required part of the clinical trial process. The findings describe patterns observed in these studies, which have been used by regulatory bodies to contextualize this type of fixed-dose combination.

However, long-term effects are not fully established for this specific combination. While research provides insight into short-term changes, data for certain groups, such as those with certain comorbidities, remain insufficient. This area of research is still emerging for specific fixed-dose pairings.


Research Gaps and Uncertainty

A summary of the evidence highlights key areas where certainty remains low or where more research is needed to provide a complete picture of the therapeutic structure.

One primary limitation is that comparative evidence is lacking for the fixed-dose combination against single-ingredient alternatives in certain indications. Furthermore, research findings were observed in some studies to have mixed outcomes, meaning not all investigations reported identical patterns of symptomatic change. The long-term outcomes are not well characterized for maintenance treatment, and subgroup findings for specific, less-common conditions are often uncertain, pointing to the need for ongoing research to contribute further to the broader evidence landscape.

Key Studies & References

  1. Combination Therapy Strategy Review – National Institutes of Health (NIH)
  2. Medazepam Chemical Compound Summary – PubChem (NCBI)
  3. Tricyclic Antidepressant Drug Class Information – MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Nobritol (FAQ)

Q: How long does it typically take for a patient to notice the beneficial effects of Nobritol?

A: Nobritol contains two active components with different onset times. Official information indicates that the anti-anxiety component may act quite rapidly—within minutes to hours. However, the antidepressant component requires more time, and full clinical effects may take several weeks (e.g., 2–4 weeks) to fully manifest.

Q: Do sexual side effects, like changes in libido, happen often with Nobritol?

A: Sexual dysfunction is a documented side effect associated with the tricyclic antidepressant component of Nobritol. This can include changes in libido (sexual desire) and orgasm. Sexual side effects should be discussed with a healthcare professional if they occur.

Q: Is feeling more anxious or agitated at the start of Nobritol treatment considered normal?

A: Regulatory documents include warnings about the potential for feeling increased anxiety, agitation, restlessness, and nervousness. These effects can occur, especially when treatment is first started or when the dosage is changed. A higher risk is noted in young adults.

Q: Can Nobritol cause blurred vision or difficulty with concentration?

A: Yes, official labeling lists blurred vision as a common side effect of Nobritol. Less commonly, the medication has also been associated with effects on cognitive function, such as disturbed concentration.

Q: Are there any specific organs, like the liver or heart, that Nobritol can potentially affect?

A: Yes, official warnings address both the heart and liver. The medication is generally not recommended for use in patients with specific heart rhythm problems. Caution is also required for patients with impaired hepatic (liver) function because this can affect how the body clears the medication.

Q: Is it safe to take Nobritol with common supplements like St. John's Wort or melatonin?

A: Official product information cautions against combining Nobritol with St. John's Wort. This is because the herbal supplement can interact with the antidepressant component and potentially increase the risk of a serious condition called serotonin syndrome. Information on melatonin interactions is less consistently addressed in regulatory documents.

Q: Does Nobritol interact with birth control pills?

A: Regulatory information suggests a potential for interaction. Some oral contraceptives may inhibit liver enzymes, which can lead to an increase in the plasma concentration of the Amitriptyline component of Nobritol. This potential increase requires awareness of possible side effects.

Q: Are there specific food or drink items to avoid while taking Nobritol?

A: Official regulatory information strictly advises avoiding alcohol (ethanol) consumption while taking Nobritol. This is because alcohol can enhance the central nervous system (CNS) depressant effects of the medicine. No specific food items are typically listed for avoidance.

Q: Can women take Nobritol while pregnant or breastfeeding?

A: The decision to use Nobritol during pregnancy or breastfeeding is a decision that requires assessment by a healthcare provider after a careful review of the potential risks and benefits. Regulatory data indicates that small amounts of the drug components can pass into breast milk.

Q: Is Nobritol ever prescribed to children or teenagers, and if so, for what reasons?

A: Nobritol is formally indicated for adults for mood/anxiety states. While one of its components is sometimes used for nocturnal bedwetting in children, regulatory agencies require a boxed warning for antidepressant use in adolescents and young adults up to age 25 due to an increased risk of suicidal thoughts and behavior.

Q: What should a patient do if they miss a scheduled dose of Nobritol?

A: Patient information generally advises taking the missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose. Dosing instructions state that a double dose should not be taken to make up for one that was forgotten.

Q: Does Nobritol need to be taken at a specific time of day for the best effect?

A: The official dosing recommendations often suggest taking the largest portion of the daily dose, or a single dose, at bedtime. This specific timing is utilized to help manage the inherent sedative properties of the drug combination.

Q: What is the relationship between Nobritol and conditions like glaucoma or seizures?

A: Nobritol is generally not recommended for use in patients with angle-closure glaucoma because the antidepressant component can worsen the condition. Official warnings also advise that caution should be used when treating patients who have a history of seizures.

Q: Can Nobritol affect sleep patterns, either causing insomnia or too much sleepiness?

A: Yes, official documents list drowsiness as a very common side effect, which is why the drug is often taken at night. Less frequently, the drug has also been associated with sleep disturbances or insomnia.

Q: Is Nobritol a controlled substance or addictive?

A: One component of Nobritol is a benzodiazepine, which is classified as a scheduled substance. Regulatory labels advise that the treatment be of limited duration to minimize the risk of dependence. Tolerance means that over time, larger amounts of the drug may be needed to achieve the same effect.

Q: Do patients typically build up a tolerance to Nobritol over time?

A: Official information for the benzodiazepine component warns of the potential for tolerance to develop with prolonged use. Tolerance means that over time, larger amounts of the drug may be needed to achieve the same effect.

Q: Can a patient drive or operate machinery while taking Nobritol?

A: The medication may cause drowsiness and impaired mental or physical abilities. Due to the risk of drowsiness, the official label advises against driving or operating hazardous machinery until the effects of the medication are known.

Q: Is it true that Nobritol can increase sun sensitivity?

A: Yes, regulatory documentation indicates that Nobritol has the potential to cause photosensitivity. This means the skin may be more sensitive to sunlight or UV light than normal, requiring protective measures when exposed.

Q: Does Nobritol have any potential to cause constipation or other digestive issues?

A: Yes, official safety information lists constipation as a common side effect. This is due to the drug's effect on the gastrointestinal tract.

Q: Are there different doses of Nobritol used for different medical problems?

A: Official dosing guidelines set a standard range for the approved condition (anxiety/depression). While the dosage depends on the patient's clinical needs and response, regulatory labels specify minimum initial doses and maximum daily limits.

Q: Why is it important to tell a dentist or surgeon you are taking Nobritol?

A: It is important to inform any healthcare professional, including a dentist or surgeon, that you are taking Nobritol. This is because the medication can interact with anesthetics and other agents used in medical procedures, potentially causing additive CNS depressant effects (increased sedation) and changes in blood pressure.

Q: Can Nobritol cause vivid dreams or nightmares?

A: Yes, according to the official product labeling, vivid dreams and nightmares are documented as possible adverse reactions associated with the use of Nobritol.

Q: How does Nobritol affect blood pressure?

A: The medication is known to cause a drop in blood pressure, specifically leading to orthostatic hypotension. This is a sudden drop in blood pressure when moving from sitting or lying down to standing.

Q: Is it normal to experience dizziness when standing up quickly while on Nobritol?

A: Yes, official safety information recognizes orthostatic hypotension as a possible adverse reaction. This condition can cause dizziness or lightheadedness when a person stands up quickly.

How should Nobritol be stored and disposed of?

How to Store and Dispose of Nobritol?

This section outlines the official, labeled requirements for the storage, handling, and disposal of this medication.

Storage Requirements

Nobritol must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The container must be kept tightly closed to protect the capsules from moisture and light, as documented in official regulatory information. It is strictly required that the medication not be frozen and be kept away from excessive heat and humidity. As with all prescription drugs, Nobritol must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Nobritol should be disposed of through an authorized drug take-back program. It is prohibited to dispose of this medication by flushing it down a sink or toilet. If a take-back program is unavailable, follow the official guidance for household disposal, which includes mixing the product with an unappealing substance like dirt before sealing and discarding it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nobritol found in:

A-Z Index: